908 Devices Inc.
7.69-0.30 (-3.75%)
Oct 29, 4:00:02 PM EDT · NasdaqGM · MASS · USD
Key Stats
Market Cap
277.50MP/E (TTM)
-Basic EPS (TTM)
-2.36Dividend Yield
0%Recent Filings
10-Q
Q2 FY2025 results
908 Devices posted solid Q2 revenue growth, hitting $13.0M, up 14% y/y from $11.5M, driven by stronger handheld device sales and recurring service income, though product margins dipped to 44% from 53% amid higher production costs and intangible amortization from the RedWave acquisition. Continuing operations showed a $12.9M net loss, widened by a $6.8M fair-value spike in contingent consideration tied to upbeat FTIR projections, yet gross profit edged up to $6.4M on volume gains. Cash swelled to $61.8M after the March Desktop Portfolio sale to Repligen for $70M, bolstering liquidity with $118.6M in cash and securities against no debt draws. The RedWave deal closed in April 2024 for $45M cash plus stock, adding $38.1M in developed tech (15-year life) and $2.5M customer relationships (8 years). Revenue relies heavily on U.S. state and local buyers, who took 58% of sales. Still, competition from bigger lab-instrument players could squeeze market share.
8-K
Q2 revenue up 14%
908 Devices reported Q2 2025 revenue of $13.0 million from continuing operations, up 14% year-over-year, with recurring revenue surging 28% to $4.7 million and representing 36% of total. The company launched VipIR for customs and acquired KAF assets for $2.75 million to secure supply chain, while completing restructuring that cut headcount 39% and square footage 44%. Adjusted gross margin dipped to 56%. It raised full-year revenue guidance to $54-56 million. Restructuring costs weighed on profits.
8-K
Board overhaul post-bioprocessing sale
908 Devices Inc. reshaped its board on July 31, 2025, with Jeff George's resignation from the Board and Compensation Committee, unrelated to disagreements but tied to the recent bioprocessing portfolio sale. Dr. Brandi C. Vann, Ph.D., a DoD veteran in nuclear, chemical, and biological defense, joined as a Class I director effective August 1, 2025, bringing expertise in CBRN threats to bolster strategy in defense tech. Tony J. Hunt stepped in as Compensation Committee Chair. This pivot sharpens focus on public health, safety, and national security applications.
8-K
Board shakeup post-bioprocessing sale
908 Devices Inc. saw board changes after selling its bioprocessing portfolio: Marcia Eisenberg resigned from the Board and Compensation Committee on June 12, 2025, unrelated to disagreements. Christopher D. Brown, a co-founder and recent Repligen VP of R&D Analytics, joined as a Class III director on June 13, 2025, bringing deep tech expertise while continuing as a consultant. Fenel M. Eloi filled the committee vacancy. Brown's return bolsters innovation strategy amid portfolio shifts.
8-K
Annual meeting results
908 Devices Inc. held its 2025 Annual Meeting on June 12, 2025, with 70.8% of shares represented. Stockholders elected Kevin J. Knopp, Ph.D., Tony J. Hunt, and Mark Spoto as Class II directors, despite some withheld votes. They also ratified PricewaterhouseCoopers LLP as auditors for the year ending December 31, 2025, with overwhelming support. Continuity intact.
ABT
Abbott Laboratories
124.43-2.18
BIO
Bio-Rad Laboratories, Inc.
319.47-10.95
BRKR
Bruker Corporation
37.74-0.98
LAB
Standard BioTools Inc.
1.19-0.08
MASI
Masimo Corporation
142.91-3.50
MLAB
Mesa Laboratories, Inc.
76.71-1.20
MOVE
Movano Inc.
6.57-0.20
MXCT
MaxCyte, Inc.
1.51-0.04
QDEL
QuidelOrtho Corporation
27.94-0.25
RPID
Rapid Micro Biosystems, Inc.
2.87-0.02